IDWeek2015 Archives - Page 3 of 5 - MPR


Novel Drug Candidate Could Block Every Strain of HIV

ATV+c or ATV+r With FTC/TDF: Effective Options for All Patients with HIV?

The combination of either atazanavir plus cobicistat (ATV+c) or atazanavir plus ritonavir (ATV+r) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) is an effective treatment option for patients who are infected with HIV regardless of race, sex, and age, with high and similar virologic success rates, a Week 48 subgroup analysis of a randomized Phase 3 trial confirmed at IDWeek 2015.

Study Urges Adding Routine Probiotic Prophylaxis for ELBW Infants

Adding routine probiotic prophylaxis in neonatal intensive care units (NICUs) is protective against necrotizing enterocolitis and bloodstream infections among extremely low birth weight (ELBW) infants, and improves their survival rates following necrotizing enterocolitis, according to authors of a multicenter quasi-experimental study in Germany.